Zynerba Pharmaceuticals (ZYNE) Upgraded to Buy at ValuEngine

ValuEngine upgraded shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) from a hold rating to a buy rating in a research report report published on Friday, ValuEngine reports.

Several other equities research analysts have also commented on the company. Roth Capital started coverage on Zynerba Pharmaceuticals in a research report on Tuesday, April 30th. They set a buy rating and a $36.00 target price on the stock. Cantor Fitzgerald restated a buy rating and set a $11.00 target price on shares of Zynerba Pharmaceuticals in a research report on Thursday, March 7th. Canaccord Genuity started coverage on Zynerba Pharmaceuticals in a research report on Monday, April 22nd. They set a buy rating and a $8.09 target price on the stock. HC Wainwright restated a buy rating on shares of Zynerba Pharmaceuticals in a research report on Monday, March 18th. Finally, LADENBURG THALM/SH SH

... read more at: https://techknowbits.com/2019/05/18/zynerba-pharmaceuticals-zyne-upgraded-to-buy-at-valuengine.html